FKBP38蛋白在乳腺癌中的表达研究

摘要 目的：探讨乳腺癌组织FK506结合蛋白38（FK506-binding protein 38,FKBP38）的表达水平及其与病理分级和临床分期的关系。方法：采用免疫组化检测100例正常乳腺组织、300例浸润性导管癌（Invasion ductal carcinoma,IDC）和59例浸润性小叶癌组织（Invasion lobular carcinoma,ILD）中FKBP38的表达水平,分析FKBP38蛋白表达水平与乳腺癌临床病理参数之间的关系。结果：免疫组化结果表明,与正常乳腺组织相比,FKBP38在浸润性导管癌及浸润性小叶癌组织中的表达水平均显著降低,具有统计学差异（P<0.0001）。通过进一步分析可知,在浸润性导管癌中,FKBP38蛋白表达水平随病理分级及临床分期的增加而降低,具有统计学差异,而FKBP38蛋白与孕激素受体（Progesterone receptor,PR）蛋白的表达呈负相关。此外,三阴性乳腺癌（Triple-negative breast cancer,TNBC）FKBP38的表达水平显著高于非三阴性乳腺癌,同样,FKBP38在TNBC的表达水平随原发性肿瘤分期的增加而降低。结论：FKBP38蛋白水平在乳腺癌患者中表达水平显著降低,并与乳腺癌的病理分级、临床分期相关。这提示FKBP38蛋白水平可作为乳腺癌诊断和治疗的潜在靶点,但其作用机制仍需进一步研究。

The Expression of FKBP38 Protein in Breast Cancer

ABSTRACT Objective: Investigate the expression and potential clinical significance of FK506-binding protein 38 (FKBP38) in breast cancer tissue. Methods: The expression of FKBP38 in 100 cases of normal breast tissue, 300 cases of invasive ductal carcinoma tissue (IDC) and 59 cases of invasive lobular carcinoma tissue (ILC) were detected by immunohistochemistry, and analyzed the relationship between the expression level of FKBP38 protein and clinicopathological parameters of breast cancer. Results: Immunohistochemical results showed that comparing with normal breast tissue, the expression levels of FKBP38 in invasive ductal carcinoma and invasive lobular carcinoma tissue significantly decreased, with a statistical difference (P<0.0001). Further analysis showed that in invasive ductal carcinoma, the expression level of FKBP38 protein was negatively correlated with the pathological grade and clinical stage, and there was a statistical difference, while the expression of FKBP38 protein was negatively correlated with the expression of PR protein. In addition, the current study demonstrated that the expression level of FKBP38 protein in triple-negative breast cancer (TNBC) was much higher than that in non-triple-negative breast cancer, and the expression of FKBP38 in TNBC was negatively correlated with the primary tumor stages. Conclusion: The expression level of FKBP38 protein significantly decreases in breast cancer patients, and it is related to the pathological grade and clinical stage of breast cancer. It is suggested that FKBP38 protein can be used as a potential target for the diagnosis and treatment of breast cancer, but the involving mechanism still needs further exploration.